OB/GYN INFORMATION CENTER
Talzenna, a poly (ADP-ribose) polymerase (PARP) inhibitor, was evaluated in EMBRACA, an open-label trial that randomized patients with gBRCAm HER2-negative locally advanced or metastatic breast cancer (N=431) to receive talazoparib 1mg or physician's choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine).
The expanded approval was supposed by safety and efficacy data from the Phase 3 ACCESS IUS trial (N=1751) in women receiving Liletta. In the trial, Liletta demonstrated >99% efficacy in preventing pregnancy for up to 5 years in a broad patient population.
Postmenopausal women with weight loss have a reduced risk for breast cancer.
The standard treatment option for premenopausal women who do not wish to get pregnant is hysterectomy.
The program strives to modify teen attitudes toward sexuality and bring about life-changing behavior.
Patients who have birth plans should be prepared to make concessions to ensure the safety of their newborn.
Many cases of vaginal foreign body are unusual and often difficult to detect.
As healthy levels of folic acid, iodine, magnesium, vitamin D, and iron demonstrate improved outcomes in pregnancy, understanding of the function of these essential nutrients on health would benefit family practitioners caring for women of childbearing age.